Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
India
/
Pharmaceuticals & Biotech
/
Shilpa Medicare
530549
Shilpa Medicare
US And EU Regulatory Pressures Will Undermine Legacy Pipelines
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 2 Analysts
Published
17 Aug 25
Updated
17 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
₹857.00
0.6% undervalued
intrinsic discount
17 Aug
₹851.95
Loading
1Y
19.1%
7D
-6.0%
Author's Valuation
₹857.0
0.6% undervalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
₹857.0
0.6% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-119m
30b
2014
2017
2020
2023
2025
2026
2028
Revenue ₹29.5b
Earnings ₹7.6b
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
20.90%
Pharma revenue growth rate
0.55%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
12.73%
Calculation
₹7.62b
Earnings '28
x
15.71x
PE Ratio '28
=
₹119.67b
Market Cap '28
₹119.67b
Market Cap '28
/
97.47m
No. shares '28
=
₹1.23k
Share Price '28
₹1.23k
Share Price '28
Discounted to 2025 @ 12.73% p.a.
=
₹857.05
Fair Value '25
